Changes in Liver and Splenic Stiffness after Direct-Acting Antiviral Therapy in Chronic Hepatitis C: A Single-Centre, Prospective, Observational Study

Table 1

Baseline characteristics of 129 patients with chronic hepatitis C who achieved a sustained virological response with DAA treatment (n =129).

Age, years	73(66-78)
Sex, male/female, n (%)	50/79 (38.8/61.2)
CH/LC, n (%)	71/58 (55.0/45.0)
ALB, g/dL	3.8(3.5-4.0)
ALT, IU/L	28(20-55)
PLT, ×10^4/μL	1.59(1.20-1.89)
FIB-4 index	3.06(2.01-4.78)
Liver stiffness (m/s)†	1.40(1.20-1.77)
Spleen stiffness (m/s)†	2.97(2.62-3.34)

†Liver and spleen stiffness were measure by point shear-wave elastography. Abbreviations: DAA, direct acting antivirals; CH, Chronic hepatitis; LC, liver cirrhosis; ALB, albumin; ALT, alanine aminotransferase; PLT, platelet count. Continuous variables were expressed as the median and first-third quartiles. Categorical variables were summarized as frequencies (percentages).